BAY2413555

BAY2413555 is an orally active, small molecule drug developed by Bayer for the treatment of chronic heart failure. It acts as a selective and reversible positive allosteric modulator (PAM) of the muscarinic acetylcholine receptor M2 (M2R), aiming to enhance parasympathetic activity in the heart and restore autonomic balance. The drug was designed to protect cardiac function and improve outcomes in patients with heart failure, particularly those with implanted cardiac defibrillator or resynchronization devices. Clinical development reached phase 1 trials but was terminated early due to preclinical findings of increased vascular inflammation in animal studies, which altered its risk-benefit profile for long-term use[1][2][3][6].